Colonic Benign Neoplasm disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLN045 MIFTS: 62	Colonic Benign Neoplasm Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Colonic Benign Neoplasm

MalaCards integrated aliases for Colonic Benign Neoplasm:

Name: Colonic Benign Neoplasm ¹¹ ¹⁴

Metastatic Colon Cancer Nos ³³

Neoplasm of the Colon ⁵

Colon Carcinoma Nos ³³

Neoplasm of Colon ¹¹

Colonic Neoplasms ⁷¹

Colon Neoplasm ¹¹

Colonic Cancer ³³

Colonic Tumor ¹¹

Colon Cancer ³³

Colonic Mass ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Cardiovascular diseases Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasms of intestine

Malignant neoplasms of large intestine

Malignant neoplasms of colon

Malignant neoplasms of colon, unspecified

Other specified malignant neoplasms of colon

External Ids:

Disease Ontology ¹¹ DOID:235

MeSH ⁴³ D003110

NCIt ⁴⁹ C2953

SNOMED-CT ⁶⁸ 126838000

ICD11 ³³ 1265576634 1265576634/other 1265576634/unspecified

UMLS ⁷¹ C0009375

Sources

Summaries for Colonic Benign Neoplasm

Disease Ontology: ¹¹ An intestinal benign neoplasm that is located in the colon.

MalaCards based summary: Colonic Benign Neoplasm, also known as metastatic colon cancer nos, is related to colorectal cancer and lynch syndrome. An important gene associated with Colonic Benign Neoplasm is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Tramadol and Ketorolac have been mentioned in the context of this disorder. Affiliated tissues include colon, lymph node and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Increased cell migration

Sources

Related Diseases for Colonic Benign Neoplasm

Diseases related to Colonic Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1468)

#	Related Disease	Score	Top Affiliating Genes
1	colorectal cancer	34.1	TP53 PALB2 MUTYH MRE11 MLH1 MIR200A
2	lynch syndrome	33.6	TP53 PALB2 MUTYH MRE11 MLH1 MIR18A
3	lynch syndrome 1	33.3	PALB2 MLH1 EPCAM CHEK2 ATM
4	familial colorectal cancer	33.2	TP53 MUTYH MLH1
5	familial adenomatous polyposis	33.1	TP53 MUTYH MLH1 KRAS HRAS CTNNB1
6	ascending colon cancer	33.0	MLH1 KRAS HRAS
7	transverse colon cancer	33.0	MLH1 KRAS HRAS
8	rectosigmoid junction neoplasm	32.9	MLH1 KRAS
9	descending colon cancer	32.9	MLH1 KRAS HRAS
10	colorectal cancer, hereditary nonpolyposis, type 6	32.7	MUTYH MLH1
11	colon adenoma	32.6	TP53 MLH1 MIR200A MIR18A MIR143 LGR5
12	colon adenocarcinoma	32.6	TP53 MLH1 KRAS HRAS CTNNB1 BRAF
13	gastric cancer	32.6	TP53 MUTYH MLH1 MIR143 KRAS ERBB3
14	colorectal adenoma	32.6	TP53 MUTYH MLH1 MIR18A MIR143 KRAS
15	muir-torre syndrome	32.5	TP53 MUTYH MLH1 HRAS EPCAM
16	desmoid tumor	32.5	TP53 MUTYH CTNNB1 APC
17	lynch syndrome 5	32.4	MLH1 BRAF APC
18	juvenile polyposis syndrome	32.4	MUTYH MLH1 APC
19	cowden syndrome 1	32.4	TP53 PALB2 MUTYH MLH1 HRAS CTNNB1
20	adenoma	32.4	TP53 MUTYH MLH1 KRAS HRAS CTNNB1
21	diffuse gastric and lobular breast cancer syndrome	32.4	TP53 PALB2 MUTYH MRE11 MLH1 KRAS
22	adenocarcinoma	32.4	TP53 MLH1 KRAS HRAS ERBB3 EPCAM
23	rectum cancer	32.4	TP53 MUTYH MLH1 MIR200A MIR18A MIR143
24	rectal benign neoplasm	32.3	TP53 MLH1 MIR143 KRAS HRAS CTNNB1
25	colitis	32.2	MLH1 CTNNB1 CHEK2 CCR6 BRAF
26	colorectal adenocarcinoma	32.0	TP53 MLH1 MIR18A MIR143 KRAS HRAS
27	mucinous adenocarcinoma	31.8	TP53 MLH1 KRAS HRAS CTNNB1
28	appendix adenocarcinoma	31.8	TP53 KRAS HRAS
29	mismatch repair cancer syndrome 1	31.7	MLH1 CTNNB1 APC
30	inherited cancer-predisposing syndrome	31.7	TP53 PALB2 MUTYH MRE11 MLH1 EPCAM
31	bap1 tumor predisposition syndrome	31.7	TP53 PALB2 MUTYH MRE11 MLH1 EPCAM
32	hepatocellular carcinoma	31.7	TP53 MLH1 MIR200A MIR18A MIR143 LGR5
33	intestinal benign neoplasm	31.7	TP53 MUTYH MLH1 MIR200A MIR18A MIR143
34	breast cancer	31.6	TP53 PALB2 MUTYH MRE11 MLH1 MIR200A
35	cecum carcinoma	31.6	MLH1 KRAS HRAS
36	lung cancer	31.5	TP53 PALB2 MLH1 MIR200A MIR18A MIR143
37	gastrointestinal system disease	31.5	MIR200A MIR18A MIR143 CCR6 APC
38	endometrial cancer	31.5	TP53 MUTYH MLH1 MIR200A KRAS HRAS
39	mismatch repair cancer syndrome	31.5	TP53 PALB2 MUTYH MLH1 KRAS HRAS
40	telangiectasis	31.5	TP53 CHEK2 CCR6 ATM
41	peripheral nervous system disease	31.5	TP53 MIR143 KRAS HRAS CTNNB1 CCR6
42	diffuse gastric cancer	31.5	TP53 PALB2 MUTYH MLH1 KRAS CTNNB1
43	ataxia-telangiectasia	31.5	TP53 MRE11 CHEK2 C11orf65 BRAF ATM
44	signet ring cell adenocarcinoma	31.5	TP53 MLH1 KRAS HRAS CTNNB1
45	pancreatic cancer	31.5	TP53 PALB2 MLH1 MIR143 KRAS HRAS
46	cholangiocarcinoma	31.5	TP53 KRAS CTNNB1 BRAF
47	esophageal cancer	31.4	TP53 MLH1 MIR200A MIR18A MIR143 KRAS
48	ovarian cancer	31.4	TP53 PALB2 MUTYH MRE11 MLH1 MIR200A
49	rectosigmoid cancer	31.4	MUTYH MLH1 KRAS HRAS
50	hematologic cancer	31.4	MLH1 MIR18A MIR143 HRAS CCR6 ATM

Graphical network of the top 20 diseases related to Colonic Benign Neoplasm:

Sources

Symptoms & Phenotypes for Colonic Benign Neoplasm

GenomeRNAi Phenotypes related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.86	MLH1 MRE11 PALB2
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.86	ATM BRAF MLH1 MRE11 PALB2 TP53
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.86	ATM C11orf65 CHEK2 MLH1 MRE11 MUTYH
4	Increased cell migration	GR00055-A-1	9.46	CTNNB1
5	Increased cell migration	GR00055-A-3	9.46	CTNNB1
6	Reduced mammosphere formation	GR00396-S	9.17	ATM BRAF CCR6 ERBB3 HRAS KRAS

MGI Mouse Phenotypes related to Colonic Benign Neoplasm:

⁴⁵ (show all 15)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.42	APC ATM BRAF CCR6 CHEK2 CTNNB1
2	neoplasm	MP:0002006	10.38	APC ATM BRAF CHEK2 CTNNB1 ERBB3
3	nervous system	MP:0003631	10.36	APC ATM BRAF CCR6 CHEK2 CTNNB1
4	endocrine/exocrine gland	MP:0005379	10.26	APC ATM BRAF CHEK2 CTNNB1 EPCAM
5	normal	MP:0002873	10.22	APC BRAF CCR6 CTNNB1 ERBB3 HRAS
6	cellular	MP:0005384	10.21	APC ATM BRAF CHEK2 CTNNB1 EPCAM
7	cardiovascular system	MP:0005385	10.17	APC ATM BRAF CCR6 CHEK2 CTNNB1
8	embryo	MP:0005380	10.16	APC ATM BRAF CTNNB1 EPCAM ERBB3
9	digestive/alimentary	MP:0005381	10.13	APC BRAF CTNNB1 EPCAM ERBB3 HRAS
10	immune system	MP:0005387	10.03	APC ATM BRAF CCR6 CHEK2 CTNNB1
11	pigmentation	MP:0001186	10.02	APC BRAF CTNNB1 ERBB3 KRAS TP53
12	craniofacial	MP:0005382	9.95	APC BRAF CTNNB1 HRAS KRAS LGR5
13	mortality/aging	MP:0010768	9.83	APC ATM BRAF CHEK2 CTNNB1 EPCAM
14	respiratory system	MP:0005388	9.76	BRAF CTNNB1 ERBB3 HRAS KRAS LGR5
15	integument	MP:0010771	9.36	APC ATM BRAF CTNNB1 ERBB3 HRAS

Sources

Drugs & Therapeutics for Colonic Benign Neoplasm

Drugs for Colonic Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 505)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Gabapentin

Approved, Investigational

Phase 4

60142-96-3

3446

Hydromorphone

Approved, Illicit

Phase 4

466-99-9, 71-68-1

5284570

Hydrocodone

Approved, Illicit, Investigational

Phase 4

125-29-1

5284569

Orphenadrine

Approved

Phase 4

83-98-7

4601

Raltitrexed

Approved, Investigational

Phase 4

112887-68-0

104758 135400182

Ethiodized oil

Approved, Investigational

Phase 4

8008-53-5

Epirubicin

Approved

Phase 4

56420-45-2

41867

Ertapenem

Approved, Investigational

Phase 4

153832-46-3

150610

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Acetaminophen

Approved

Phase 4

103-90-2

1983

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Glucagon

Approved

Phase 4

16941-32-5

16133228 16186314

Magnesium oxide

Approved

Phase 4

1309-48-4

14792

Tocopherol

Approved, Investigational

Phase 4

1406-66-2

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Droperidol

Approved, Vet_approved

Phase 4

548-73-2

3168

Celecoxib

Approved, Investigational

Phase 4

169590-42-5

2662

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Tranexamic acid

Approved

Phase 4

1197-18-8

5526

Mitomycin

Approved

Phase 4

50-07-7

5746

Simethicone

Approved

Phase 4

8050-81-5

Rivaroxaban

Approved

Phase 4

366789-02-8

9875401

Sodium sulfate

Approved, Vet_approved

Phase 4

7757-82-6

Sodium citrate

Approved, Investigational

Phase 4

68-04-2

23431961

DL-alpha-Tocopherol

Approved, Experimental, Investigational, Nutraceutical, Vet_approved

Phase 4

59-02-9, 10191-41-0

2116 14985

Arginine

Approved, Investigational, Nutraceutical

Phase 4

74-79-3

6322

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 4

77-92-9

311

Chlorotrianisene

Investigational, Withdrawn

Phase 4

569-57-3

11289

Tocotrienol

Investigational

Phase 4

6829-55-6

9929901

Acetaminophen, hydrocodone drug combination

Phase 4

Ketorolac Tromethamine

Phase 4

Antiparkinson Agents

Phase 4

Anticonvulsants

Phase 4

Cytochrome P-450 Enzyme Inhibitors

Phase 4

Muscarinic Antagonists

Phase 4

Cholinergic Antagonists

Phase 4

Cholinergic Agents

Phase 4

Folic Acid Antagonists

Phase 4

Anesthetics

Phase 4

Neurotransmitter Agents

Phase 4

Anti-Anxiety Agents

Phase 4

Analgesics, Opioid

Phase 4

Narcotics

Phase 4

Hormone Antagonists

Phase 4

Polyethylene glycol 3350

Phase 4

Glucagon-Like Peptide 1

Phase 4

Pirinitramide

Phase 4

Interventional clinical trials:

(show top 50) (show all 1335)

#	Name	Status	NCT ID	Phase	Drugs
1	Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial.	Unknown status	NCT02958566	Phase 4	Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
2	A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer	Unknown status	NCT02887365	Phase 4	tegafur-uracil
3	Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity	Unknown status	NCT04269369	Phase 4	5-Fluorouracil
4	A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases	Unknown status	NCT02557490	Phase 4	oxaliplatin and raltitrexed
5	Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial	Unknown status	NCT02746432	Phase 4	Hyper insulinemic euglycemic clamp
6	Endo-Laparoscopic Approach Versus Conventional Open Surgery in the Management of Obstructing Left-sided Colon Cancer: A Randomized Trial	Completed	NCT00654212	Phase 4
7	Konzentrationen Von Ertapenem in Kolorektalem Gewebe	Completed	NCT00535652	Phase 4	Ertapenem
8	Compression Anastomosis: Initial Clinical Experience With the ColonRingTM	Completed	NCT01056913	Phase 4
9	Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV	Completed	NCT00263055	Phase 4	oxaliplatin
10	Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates	Completed	NCT00628147	Phase 4
11	Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial	Completed	NCT02078726	Phase 4	Glucagon
12	An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C.	Completed	NCT00502671	Phase 4	capecitabine [Xeloda]
13	Effect of Postoperative Laxative on Bowel Function After Colonic Surgery	Completed	NCT00427492	Phase 4	Magnesia;Placebo
14	An Expanded Access Program of AvastinTM (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum	Completed	NCT02582970	Phase 4	5-Fluorouracil;Bevacizumab;Irinotecan;Oxaliplatin
15	Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'	Completed	NCT00577031	Phase 4	bevacizumab [Avastin];Oxaliplatin;Xeloda
16	Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery	Completed	NCT02314871	Phase 4	Piritramide;Morphine
17	Preoperative Use of the High Protein ONS vs Immunoenhancing ONS in Gastrointestinal Cancer Patients Undergoing Surgery	Completed	NCT03980704	Phase 4	IMPACT;resource protein
18	Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer	Completed	NCT02231203	Phase 4	Omegaven;Placebo
19	A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy	Completed	NCT01170754	Phase 4	PEG-3350 and Gatorade;Golytely 4 liters
20	Patient Satisfaction With Propofol for Out Patient Colonoscopy: A Prospective, Randomized, Double-Blind Study	Completed	NCT02937506	Phase 4	Propofol;Fentanyl Plus Midazolam
21	Clinical Efficacy of Chemotherapy Combined With Cytokine-induced Killer in Treatment of Patients With Colon Cancer	Completed	NCT03084809	Phase 4	Cytokine-induced killer cells+ FOLFOX4;FOLFOX4
22	Contribution to the Study of Inflammatory Response in Laparoscopic vs Open Colon Cancer Surgery	Completed	NCT00942461	Phase 4
23	Improving Perioperative Pain Management for Laparoscopic Surgery Due to Colon Cancer Using the Ultrasound-guided Transmuscular Quadratus Lumborum Block. A Double Blind, Randomized, Placebo Controlled Trial.	Completed	NCT03570541	Phase 4	Ropivacaine;Acetaminophen;Morphine;Saline
24	The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery	Completed	NCT02052557	Phase 4	Bupivacaine;Bupivacaine liposome suspension
25	Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy	Completed	NCT01169220	Phase 4	Go-Lytely;Go Lytely
26	Assessment of the Effect of Dexmedetomidine in the Management of Postoperative Pain When Combined With Fentanyl in the Patient-controlled Analgesia	Completed	NCT01373021	Phase 4	Fentanyl;Dexmedetomidine
27	Low-dose Neuroleptanalgesia Reduce the Occurrences of Postoperative Delirium in Elderly Patients Undergoing Non-cardiac Major Surgery : a Randomized Controlled Trial	Recruiting	NCT05068180	Phase 4	low-dose neuroleptanalgesia;Placebo
28	A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer	Recruiting	NCT01975064	Phase 4	Propofol;Sevoflurane
29	Influence of Argipressin on Blood Loss and Inflammatory Response During Hepatic Resection; a Double-blinded, Randomized Placebo-controlled Trial	Recruiting	NCT05293041	Phase 4	Argipressin;Placebo
30	Usage of Tranexamic Acid During Colonic Endoscopic Resection Procedures for Reduction Intraprocedural and Postprocedural Bleeding	Recruiting	NCT05345613	Phase 4	Tranexamic acid;Standard
31	Phase IV Multicentric Clinical Trial to Evaluate the Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Mytomicin-C After Complete Surgical Cytoreduction in Patients With Colon Cancer Peritoneal Metastases	Recruiting	NCT05250648	Phase 4	complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
32	Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block in Minimally Invasive Colon Surgery: A Randomized Controlled Multicentre Clinical Trial	Recruiting	NCT04311099	Phase 4	Active drug;Placebo
33	Evaluation of Anticancer Effect of Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer	Recruiting	NCT03645187	Phase 4	FOLFERI;Folferi and celecoxib
34	Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract	Not yet recruiting	NCT02688699	Phase 4
35	Evaluation of Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in the Surgical Treatment of Colorectal Cancer	Not yet recruiting	NCT05303818	Phase 4	Rivaroxaban 10 MG
36	Comparison of Low-volume Versus High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis: a Randomized Non-inferiority Trial	Not yet recruiting	NCT04709770	Phase 4	2-liters polyethylene glycol with citrate and simethicone;4-liters polyethylene glycol with simethicone
37	Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor	Terminated	NCT02015923	Phase 4	Chemotherapy- scheme
38	A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Colon Cancer	Unknown status	NCT00387842	Phase 3
39	Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group Clinical Trial	Unknown status	NCT02777437	Phase 2, Phase 3	XELOX or FOLFOX chemotherapy
40	The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak and Short-term Outcomes in Robotic Colorectal Surgery: A Prospective Randomized Trial	Unknown status	NCT02598414	Phase 2, Phase 3
41	The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy	Unknown status	NCT02280278	Phase 3	Adjuvant chemotherapy
42	FOxTROT - Fluoropyrimidine, Oxaliplatin and Targeted Receptor Pre-Operative Therapy: a Controlled Trial in High-Risk Operable Colon Cancer	Unknown status	NCT00647530	Phase 2, Phase 3	capecitabine;fluorouracil;oxaliplatin
43	Effect of TCM-TSKSR on Completion Rates of Chemotherapy in Patients With Stage II & III Colon Cancer: A Randomized Placebo-Controlled Clinical Trial	Unknown status	NCT03716518	Phase 3	Tonifying Spleen and Kidney Sequential Regimen;Placebo of 'Tonifying Spleen and Kidney Sequential Regimen
44	5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03).	Unknown status	NCT00046995	Phase 3	carboplatin;fluorouracil;leucovorin calcium
45	A Randomized Controlled Trial Comparing the Outcomes of Patients Who Undergo Single Port Laparoscopic Colectomy and Conventional Laparoscopic Colectomy for Colonic Neoplasia	Unknown status	NCT01101672	Phase 2, Phase 3
46	A Randomized Phase III Study Investigating the Role of Oxaliplatin Duration (3 Months Versus 6 Months) in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Therapy for Patients With Stage II/III Colon Cancer	Unknown status	NCT01092481	Phase 3	oxaliplatin
47	Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors	Unknown status	NCT00091312	Phase 3	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
48	Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts	Unknown status	NCT00002455	Phase 3
49	Randomized Phase III Study Assessing the Interest of Primary Tumor Resection in Patients With Asymptomatic Colon Cancer and Unresectable Synchronous Liver Metastases.	Unknown status	NCT02363049	Phase 3	Chemotherapy
50	Complete Mesocolic Excision (CME) With Central Supplying Vessel Ligation (CVL) Compared With Conventional Surgery for Colon Cancer: a Double-blinded Randomized Study	Unknown status	NCT02526836	Phase 2, Phase 3

Search NIH Clinical Center for Colonic Benign Neoplasm

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carmustine

Fluorouracil

irinotecan

Irinotecan hydrochloride

Levamisole

Lomustine

Sources

Genetic Tests for Colonic Benign Neoplasm

Sources

Anatomical Context for Colonic Benign Neoplasm

Organs/tissues related to Colonic Benign Neoplasm:

FMA: Colon

MalaCards : Colon, Lymph Node, Liver, Breast, Prostate, Lung, T Cells

Sources

Publications for Colonic Benign Neoplasm

Articles related to Colonic Benign Neoplasm:

(show top 50) (show all 33103)

#	Title	Authors	PMID	Year
1	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. ⁶² ⁵	Prahallad A...Bernards R	22281684	2012
2	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
3	Oncogenic ERBB3 mutations in human cancers. ⁵	Jaiswal BS...Seshagiri S	23680147	2013
4	Unexpected adhesive bowel obstruction after endoscopic submucosal dissection of early sigmoid colon cancer. ⁶²	Seki K...Saito Y	36466039	2023
5	RNF43 induces the turnover of protease-activated receptor 2 in colon cancer. ⁶²	Nag JK...Bar-Shavit R	36468684	2023
6	The burden of colon cancer attributable to modifiable factors-The Norwegian Women and Cancer Study. ⁶²	Lukic M...Rylander C	36054722	2023
7	Investigation of the effects of isoeugenol-based phenolic compounds on migration and proliferation of HT29 colon cancer cells at cellular and molecular level. ⁶²	Bilgin S...Koc E	36375352	2023
8	Metabolomic Characterization of the Antiproliferative Activity of Bioactive Compounds from Fruit By-Products Against Colon Cancer Cells. ⁶²	Alvarez-Rivera G...Cifuentes A	36152149	2023
9	ZDHHC9 promotes colon tumor growth by inhibiting effector T cells. ⁶²	Chong X...An H	36419754	2023
10	Breast metastasis of signet ring cell carcinoma from the colon: a case report. ⁶²	Wang X...Lu Y	36451153	2022
11	CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA. ⁶²	Xiao H...Dixon DA	35130122	2022
12	Energy balance-related factors in childhood and adolescence and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status. ⁶²	Jenniskens JCA...van den Brandt PA	36177801	2022
13	Comparison of Robotic and Laparoscopic Colectomies Using the 2019 ACS NSQIP Database. ⁶²	Soliman SS...Nemeth ZH	36455896	2022
14	An integrated map of fibroblastic populations in human colon mucosa and cancer tissues. ⁶²	Li S...Mo X	36463319	2022
15	Medullary carcinoma of the colon: A comprehensive analysis of the National Cancer Database. ⁶²	Jabbal IS...Wexner S	36446307	2022
16	Associations of cigarette smoking, alcohol drinking and body mass index with survival after colorectal cancer diagnosis by anatomic subsite: a prospective patient cohort study in Japan. ⁶²	Minami Y...Miura K	36007230	2022
17	The Association of Vitamin D3 With Early Anastomotic Leakage in Patients Undergoing Hemicolectomy Surgery. ⁶²	Layeg H...Amestejani M	34968156	2022
18	Ursolic and oleanolic acids in combination therapy inhibit migration of colon cancer cells through down-regulation of the uPA/uPAR-dependent MMPs pathway. ⁶²	Piet M...Paduch R	36191607	2022
19	[Corrigendum] Resveratrol inhibits the invasion and metastasis of colon cancer through reversal of epithelial‑mesenchymal transition via the AKT/GSK‑3β/Snail signaling pathway. ⁶²	Yuan L...Ruan S	36222306	2022
20	CCL26 silence represses colon cancer by inhibiting the EMT signaling pathway. ⁶²	Sun A...Jiang X	36156375	2022
21	circRNA PLOD2 promotes tumorigenesis and Warburg effect in colon cancer by the miR-513a-5p/SIX1/LDHA axis. ⁶²	Li Y...Ma H	36071678	2022
22	The treatment efficacy of three-layered functional polymer materials as drug carrier for orthotopic colon cancer. ⁶²	Liu Z...Li J	36101475	2022
23	MiR-17-5p Targets and Downregulates CADM2, Activating the Malignant Phenotypes of Colon Cancer Cells. ⁶²	Wang Y...Li H	35696058	2022
24	Trends in Adjuvant Chemotherapy Use Among Stage III Colon Cancer in Non-Elderly and Low Comorbidity Patients. ⁶²	El Hajj J...Kazmi SM	36283915	2022
25	Glomerular Microangiopathy with Cellular Crescent-like Formation and Endotheliopathy Due to Ramucirumab Treatment for Metastatic Sigmoid Colon Cancer. ⁶²	Yoshimura Y...Ubara Y	35569979	2022
26	The measured distance between tumor cells and the peritoneal surface predicts the risk of peritoneal metastases and offers an objective means to differentiate between pT3 and pT4a colon cancer. ⁶²	Zwanenburg ES...COLOPEC trial collaborators	36123540	2022
27	Correction to: Impact of preoperative smoking on patients undergoing right hemicolectomies for colon cancer. ⁶²	Badiani S...Berney CR	35895110	2022
28	Tumor-to-tumor metastasis of colon cancer metastasizing to a pancreatic neuroendocrine tumor associated with von Hippel-Lindau disease: a case report. ⁶²	Natsui H...Terai S	35951216	2022
29	Expression and Prognostic Significance of Stem Cell Marker CD133 in Survival Rate of Patients with Colon Cancer. ⁶²	Ehteram H...Haddad Kashani H	35980560	2022
30	Long-term Bowel Dysfunction and Decline in Quality of Life Following Surgery for Colon Cancer: Call for Personalized Screening and Treatment. ⁶²	Verkuijl SJ...Broens PMA	35982522	2022
31	Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. ⁶²	Teufel A...Klinkhammer-Schalke M	35934636	2022
32	PCDH7 knockdown potentiates colon cancer cells to chemotherapy via inducing ferroptosis and changes in autophagy through restraining MEK1/2/ERK/c-Fos axis. ⁶²	Liu Z...Wang B	35926236	2022
33	Colon Targeted Eudragit Coated Beads Loaded with Optimized Fluvastatin-Scorpion Venom Conjugate as a Potential Approach for Colon Cancer Therapy: In Vitro Anticancer Activity and In Vivo Colon Imaging. ⁶²	Ahmed OAA...Mady FM	36007556	2022
34	Overexpression of HOXB13 predicts poor prognosis in patients with colon cancer. ⁶²	Gao DZ...Zhao XF	35715295	2022
35	Gnetum montanum extract induces apoptosis by inhibiting the activation of AKT in SW480 human colon cancer cells. ⁶²	Pan X...Hao E	35587342	2022
36	Development of nanocubosomes co-loaded with dual anticancer agents curcumin and temozolomide for effective Colon cancer therapy. ⁶²	Almoshari Y...Ali Khan B	35942514	2022
37	Antitumoral effect of novel synthetic 8-hydroxy-2-((4-nitrophenyl)thio)naphthalene-1,4-dione (CNN16) via ROS-mediated DNA damage, apoptosis and anti-migratory effect in colon cancer cell line. ⁶²	da Silva EL...Montenegro RC	36208702	2022
38	Retraction statement: High-intensity focused ultrasound inhibits invasion and metastasis of colon cancer cells by enhancing microRNA-124-mediated suppression of STAT3. ⁶²		36377839	2022
39	A modulatory effect of L-arginine supplementation on anticancer effects of chemoimmunotherapy in colon cancer-bearing aged mice. ⁶²	Ishitobi K...Harada M	36461608	2022
40	Folate decorated lipid chitosan hybrid nanoparticles of 5-fluorouracil for enhanced anticancer efficacy against colon cancer. ⁶²	Khan S...Khan MM	36174854	2022
41	Nobiletin is capable of regulating certain anti-cancer pathways in a colon cancer cell line. ⁶²	Kisacam MA	36454256	2022
42	Discovery of Orally Bioavailable N-Benzylpiperidinol Derivatives as Potent and Selective USP7 Inhibitors with In Vivo Antitumor Immunity Activity against Colon Cancer. ⁶²	Li X...Wen X	36454192	2022
43	[What is confirmed in the treatment of colon cancer?] ⁶²	Lordick F...Gockel I	36380005	2022
44	Resveratrol inhibits proliferation and induces apoptosis via the Hippo/YAP pathway in human colon cancer cells. ⁶²	Qin X...He B	36335870	2022
45	Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. ⁶²	Corry SM...Dunne PD	35477539	2022
46	Colon cancer and colorectal cancer: Prevention and treatment by potential natural products. ⁶²	Islam MR...Simal-Gandara J	36202214	2022
47	Robotic complete mesocolic excision of right-sided colon cancer with bulky lymph node metastases using the da Vinci® Si™ system: A case report. ⁶²	Fujino S...Oka Y	36311687	2022
48	Identifying novel interactions of the colon-cancer related APC protein with Wnt-pathway nuclear transcription factors. ⁶²	Al-Thani NM...Malek JA	36457029	2022
49	Hypoxia-inducible factors, mTOR, and astrin constitute an integrative regulatory network in colon cancer cells. ⁶²	Saint-Martin A...Robles-Flores M	36111249	2022
50	Successful left hepatic trisectionectomy after portal vein embolization for colon cancer liver metastasis in a patient with right-sided ligamentum teres. ⁶²	Urade T...Fukumoto T	36088617	2022

Sources

Genes for Colonic Benign Neoplasm

Genes related to Colonic Benign Neoplasm (7 elite genes):

(show top 50) (show all 103)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	407.24	Pathogenic ⁵ DISEASES inferred ¹⁴
2	MLH1	MutL Homolog 1	Protein Coding	406.48	Pathogenic ⁵ DISEASES inferred ¹⁴
3	EPCAM	Epithelial Cell Adhesion Molecule	Protein Coding	405.23	Pathogenic ⁵ DISEASES inferred ¹⁴
4	ATM	ATM Serine/Threonine Kinase	Protein Coding	404.78	Pathogenic ⁵ DISEASES inferred ¹⁴
5	PALB2	Partner And Localizer Of BRCA2	Protein Coding	402.95	Pathogenic ⁵ DISEASES inferred ¹⁴
6	C11orf65	Chromosome 11 Open Reading Frame 65	Protein Coding	400	Pathogenic ⁵
7	MRE11	MRE11 Homolog, Double Strand Break Repair Nuclease	Protein Coding	400	Pathogenic ⁵
8	MUTYH	MutY DNA Glycosylase	Protein Coding	30.3	Likely pathogenic ⁵ DISEASES inferred ¹⁴
9	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	29.06	Likely pathogenic ⁵ DISEASES inferred ¹⁴	22281684 25157968
10	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	28.96	Likely pathogenic ⁵ DISEASES inferred ¹⁴	23680147
11	CHEK2	Checkpoint Kinase 2	Protein Coding	28.91	Likely pathogenic ⁵ DISEASES inferred ¹⁴
12	MIR18A	MicroRNA 18a	RNA Gene	8.2	DISEASES inferred ¹⁴ ¹⁴
13	MIR143	MicroRNA 143	RNA Gene	8.03	DISEASES inferred ¹⁴ ¹⁴
14	CTNNB1	Catenin Beta 1	Protein Coding	7.32	DISEASES inferred ¹⁴
15	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	7.16	DISEASES inferred ¹⁴ ¹⁴
16	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.96	DISEASES inferred ¹⁴
17	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.89	DISEASES inferred ¹⁴
18	TP53	Tumor Protein P53	Protein Coding	6.73	DISEASES inferred ¹⁴
19	MIR200A	MicroRNA 200a	RNA Gene	6.67	DISEASES inferred ¹⁴ ¹⁴
20	LGR5	Leucine Rich Repeat Containing G Protein-Coupled Receptor 5	Protein Coding	6.62	DISEASES inferred ¹⁴
21	CDX2	Caudal Type Homeobox 2	Protein Coding	6.6	DISEASES inferred ¹⁴
22	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	6.6	DISEASES inferred ¹⁴
23	MIR15A	MicroRNA 15a	RNA Gene	6.58	DISEASES inferred ¹⁴ ¹⁴
24	MIR199A1	MicroRNA 199a-1	RNA Gene	6.47	DISEASES inferred ¹⁴ ¹⁴
25	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.41	DISEASES inferred ¹⁴
26	CCND1	Cyclin D1	Protein Coding	6.34	DISEASES inferred ¹⁴
27	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	6.33	DISEASES inferred ¹⁴
28	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.31	DISEASES inferred ¹⁴
29	IL6	Interleukin 6	Protein Coding	6.26	DISEASES inferred ¹⁴
30	MSH2	MutS Homolog 2	Protein Coding	6.19	DISEASES inferred ¹⁴
31	CDH1	Cadherin 1	Protein Coding	6.13	DISEASES inferred ¹⁴
32	MSH6	MutS Homolog 6	Protein Coding	6.07	DISEASES inferred ¹⁴
33	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	6.03	DISEASES inferred ¹⁴
34	IL17A	Interleukin 17A	Protein Coding	6.03	DISEASES inferred ¹⁴
35	SERPINA3	Serpin Family A Member 3	Protein Coding	5.96	DISEASES inferred ¹⁴ ¹⁴
36	H2AC18	H2A Clustered Histone 18	Protein Coding	5.96	DISEASES inferred ¹⁴ ¹⁴
37	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	5.94	DISEASES inferred ¹⁴
38	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.92	DISEASES inferred ¹⁴
39	IL10	Interleukin 10	Protein Coding	5.9	DISEASES inferred ¹⁴
40	TNF	Tumor Necrosis Factor	Protein Coding	5.9	DISEASES inferred ¹⁴
41	AXIN2	Axin 2	Protein Coding	5.84	DISEASES inferred ¹⁴
42	IL1B	Interleukin 1 Beta	Protein Coding	5.84	DISEASES inferred ¹⁴
43	SMAD4	SMAD Family Member 4	Protein Coding	5.82	DISEASES inferred ¹⁴
44	ACTB	Actin Beta	Protein Coding	5.8	DISEASES inferred ¹⁴
45	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	5.74	DISEASES inferred ¹⁴
46	EGF	Epidermal Growth Factor	Protein Coding	5.65	DISEASES inferred ¹⁴
47	HNF4A	Hepatocyte Nuclear Factor 4 Alpha	Protein Coding	5.65	DISEASES inferred ¹⁴
48	CASP3	Caspase 3	Protein Coding	5.63	DISEASES inferred ¹⁴
49	KRT20	Keratin 20	Protein Coding	5.63	DISEASES inferred ¹⁴
50	BCL2	BCL2 Apoptosis Regulator	Protein Coding	5.62	DISEASES inferred ¹⁴

Sources

Variations for Colonic Benign Neoplasm

ClinVar genetic disease variations for Colonic Benign Neoplasm:

⁵ (show all 14)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	EPCAM	NM_002354.3(EPCAM):c.903+1G>A	SNV	Pathogenic	1244227		GRCh37: 2:47612350-47612350 GRCh38: 2:47385211-47385211
2	MRE11	NM_005591.4(MRE11):c.1726C>T (p.Arg576Ter)	SNV	Pathogenic	184445	rs774277300	GRCh37: 11:94180442-94180442 GRCh38: 11:94447276-94447276
3	APC	NM_000038.6(APC):c.1370C>A (p.Ser457Ter)	SNV	Pathogenic	433620	rs1060503333	GRCh37: 5:112157650-112157650 GRCh38: 5:112821953-112821953
4	MLH1	NM_000249.4(MLH1):c.1A>T (p.Met1Leu)	SNV	Pathogenic	1255698		GRCh37: 3:37035039-37035039 GRCh38: 3:36993548-36993548
5	ATM, C11orf65	NM_000051.4(ATM):c.6415G>T (p.Glu2139Ter)	SNV	Pathogenic	651311	rs1339238483	GRCh37: 11:108190748-108190748 GRCh38: 11:108320021-108320021
6	MLH1	NM_000249.4(MLH1):c.790+1G>A	SNV	Pathogenic	90356	rs267607789	GRCh37: 3:37056036-37056036 GRCh38: 3:37014545-37014545
7	PALB2	NM_024675.4(PALB2):c.1671_1674del (p.Ile558fs)	MICROSAT	Pathogenic	410108	rs1060502734	GRCh37: 16:23646193-23646196 GRCh38: 16:23634872-23634875
8	ERBB3	NM_001982.4(ERBB3):c.850G>A (p.Gly284Arg)	SNV	Likely Pathogenic	376167	rs1057519803	GRCh37: 12:56481922-56481922 GRCh38: 12:56088138-56088138
9	MUTYH	NM_001048174.2(MUTYH):c.420+19_420+31del	DEL	Likely Pathogenic	406825	rs781222233	GRCh37: 1:45798559-45798571 GRCh38: 1:45332887-45332899
10	CHEK2	NM_007194.4(CHEK2):c.917G>C (p.Gly306Ala)	SNV	Likely Pathogenic	128089	rs587780192	GRCh37: 22:29095917-29095917 GRCh38: 22:28699929-28699929
11	BRAF	NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)	SNV	Likely Pathogenic	13961	rs113488022	GRCh37: 7:140453136-140453136 GRCh38: 7:140753336-140753336
12	BRAF	NM_004333.6(BRAF):c.1799_1800delinsAA (p.Val600Glu)	INDEL	Likely Pathogenic	376069	rs121913377	GRCh37: 7:140453135-140453136 GRCh38: 7:140753335-140753336
13	TP53	NM_000546.6(TP53):c.1060C>A (p.Gln354Lys)	SNV	Uncertain Significance	231485	rs755394212	GRCh37: 17:7573967-7573967 GRCh38: 17:7670649-7670649
14	MLH1	NM_000249.4(MLH1):c.884+3A>C	SNV	Uncertain Significance	1255699		GRCh37: 3:37059093-37059093 GRCh38: 3:37017602-37017602

Sources

Expression for Colonic Benign Neoplasm

Search GEO for disease gene expression data for Colonic Benign Neoplasm.

Sources

Pathways for Colonic Benign Neoplasm

Pathways related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 65)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.8	APC ATM BRAF CCR6 CHEK2 CTNNB1
2	Signal Transduction ⁶⁶	13.79	TP53 LGR5 KRAS HRAS ERBB3 CTNNB1
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.75	TP53 PALB2 MUTYH MRE11 MLH1 KRAS
4	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.48	TP53 KRAS HRAS ERBB3 CTNNB1 BRAF
5	Homology Directed Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex ⁶⁶ DNA Double-Strand Break Repair ⁶⁶ DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Processing of DNA double-strand break ends ⁶⁶	13.19	TP53 PALB2 MUTYH MRE11 MLH1 CHEK2
6	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.89	TP53 MRE11 MLH1 KRAS HRAS CHEK2
7	Alzheimer's disease and miRNA effects ⁷⁴ Show member pathways Alzheimer's disease ⁷⁴	12.85	KRAS HRAS CTNNB1 BRAF APC
8	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.85	KRAS HRAS ERBB3 CTNNB1 BRAF
9	ncRNAs involved in Wnt signaling in hepatocellular carcinoma ⁷⁴ Show member pathways lncRNA in canonical Wnt signaling and colorectal cancer ⁷⁴ Wnt signaling ⁷⁴ Wnt signaling pathway and pluripotency ⁷⁴ Wnt Signaling Pathways ⁶⁵	12.82	TP53 MIR18A LGR5 CTNNB1 APC
10	Homologous DNA Pairing and Strand Exchange ⁶⁶ Show member pathways Defective Base Excision Repair Associated with NEIL1 ⁶⁶ Defective homologous recombination repair (HRR) due to BRCA2 loss of function ⁶⁶ Diseases of Base Excision Repair ⁶⁶ Diseases of DNA Double-Strand Break Repair ⁶⁶ Diseases of DNA repair ⁶⁶ Fanconi anemia pathway ⁶¹ Fanconi Anemia Pathway ⁶⁶ HDR through Homologous Recombination (HRR) ⁶⁶ HDR through Single Strand Annealing (SSA) ⁶⁶ Impaired BRCA2 binding to RAD51 ⁶⁶ Presynaptic phase of homologous DNA pairing and strand exchange ⁶⁶	12.75	PALB2 MUTYH MRE11 MLH1 ATM
11	Malignant pleural mesothelioma ⁷⁴	12.7	TP53 HRAS CTNNB1 ATM APC
12	DNA repair pathways, full network ⁷⁴ Show member pathways Defective Mismatch Repair Associated With MSH2 ⁶⁶ Defective Mismatch Repair Associated With MSH3 ⁶⁶ Defective Mismatch Repair Associated With MSH6 ⁶⁶ Diseases of Mismatch Repair (MMR) ⁶⁶ Dual Incision in GG-NER ⁶⁶ Homologous recombination ⁷⁴ Mismatch Repair ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) ⁶⁶ Non-homologous end joining ⁷⁴ Nucleotide excision repair ⁷⁴ Nucleotide excision repair in xeroderma pigmentosum ⁷⁴ Nucleotide Excision Repair Pathway ⁶⁴	12.62	PALB2 MUTYH MRE11 MLH1 ATM
13	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.62	TP53 MLH1 KRAS HRAS CTNNB1 BRAF
14	DNA Damage ³	12.5	TP53 MUTYH MRE11 MLH1 CHEK2 ATM
15	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.45	TP53 HRAS ERBB3 CTNNB1 BRAF
16	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.44	TP53 KRAS HRAS ERBB3 CTNNB1 BRAF
17	MAPK signaling pathway ⁷⁴	12.41	BRAF HRAS KRAS TP53
18	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.4	KRAS HRAS CTNNB1 BRAF
19	DNA Double Strand Break Response ⁶⁶ Show member pathways Nonhomologous End-Joining (NHEJ) ⁶⁶ Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks ⁶⁶ Sensing of DNA Double Strand Breaks ⁶⁶	12.37	TP53 MRE11 CHEK2 ATM
20	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.37	KRAS HRAS ERBB3 CTNNB1 BRAF APC
21	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.28	TP53 KRAS HRAS ERBB3 CTNNB1 CHEK2
22	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.21	TP53 KRAS HRAS ERBB3 BRAF
23	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.19	TP53 KRAS HRAS CTNNB1
24	NGF Pathway ⁶⁴ Show member pathways MAPK and NFkB signaling pathways inhibited by Yersinia YopJ ⁷⁴ TRKA Signaling ⁶⁴	12.17	BRAF HRAS KRAS TP53
25	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.1	TP53 MRE11 CHEK2 ATM
26	Colorectal Cancer Metastasis ⁶⁴	12.1	TP53 MLH1 KRAS CTNNB1 BRAF APC
27	G12-G13 in Cellular Signaling ⁶⁴	12.03	KRAS HRAS CTNNB1 APC
28	mTOR Signaling ⁶⁵	11.99	APC BRAF ERBB3 KRAS LGR5 TP53
29	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.89	TP53 MRE11 CHEK2 ATM
30	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.83	TP53 HRAS CTNNB1
31	ATM Pathway ⁶⁴ Show member pathways ATM signaling pathway ⁷⁴	11.81	ATM CHEK2 MRE11 TP53
32	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.8	KRAS HRAS BRAF
33	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.8	TP53 KRAS HRAS
34	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.8	ATM CHEK2 MRE11 TP53
35	MAPK Signaling: Oxidative Stress ⁶⁵	11.79	TP53 KRAS BRAF
36	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.76	TP53 CHEK2 ATM
37	Head and neck squamous cell carcinoma ⁷⁴	11.74	TP53 KRAS HRAS CTNNB1
38	DNA damage response (only ATM dependent) ⁷⁴	11.74	TP53 KRAS HRAS CTNNB1 ATM APC
39	Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ⁶¹	11.73	HRAS CTNNB1 APC
40	miRNAs involved in DNA damage response ⁷⁴	11.68	TP53 MIR18A MIR143 ATM
41	Integrated breast cancer pathway ⁷⁴	11.68	TP53 MRE11 KRAS CTNNB1 CHEK2 BRAF
42	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.67	TP53 HRAS ATM
43	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	11.66	KRAS HRAS BRAF
44	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	11.66	TP53 MRE11 KRAS HRAS CTNNB1 BRAF
45	BDNF-TrkB signaling ⁷⁴ Show member pathways Synaptic signaling pathways associated with autism spectrum disorder ⁷⁴	11.65	BRAF HRAS KRAS
46	Agrin Interactions at Neuromuscular Junction ⁶⁴	11.62	KRAS HRAS ERBB3
47	p53 pathway ⁶¹	11.56	TP53 CHEK2 ATM
48	DNA IR-damage and cellular response via ATR ⁷⁴	11.54	TP53 PALB2 MRE11 MLH1 CHEK2 ATM
49	Heart development ⁷⁴	11.53	MIR143 ERBB3 CTNNB1
50	Cell cycle Role of 14-3-3 proteins in cell cycle regulation ²² Show member pathways 14-3-3 and Cell Cycle Regulation ⁶⁴	11.51	TP53 CHEK2 ATM

Sources

GO Terms for Colonic Benign Neoplasm

Cellular components related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	lateral plasma membrane	GO:0016328	9.23	ERBB3 EPCAM CTNNB1 APC

Biological processes related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.34	TP53 PALB2 MRE11 ERBB3 CTNNB1 BRAF
2	positive regulation of gene expression	GO:0010628	10.25	TP53 KRAS HRAS ERBB3 CTNNB1 BRAF
3	negative regulation of neuron apoptotic process	GO:0043524	10.19	KRAS HRAS ERBB3 BRAF
4	MAPK cascade	GO:0000165	10.18	KRAS HRAS CTNNB1 BRAF
5	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	10.08	MLH1 CHEK2 ATM
6	DNA repair	GO:0006281	10.08	ATM CHEK2 MLH1 MRE11 MUTYH PALB2
7	thymus development	GO:0048538	10.07	ATM BRAF CTNNB1
8	double-strand break repair	GO:0006302	10.06	TP53 MRE11 CHEK2 ATM
9	somitogenesis	GO:0001756	10.04	ATM PALB2 TP53
10	T cell differentiation in thymus	GO:0033077	10.03	TP53 CTNNB1 BRAF
11	double-strand break repair via nonhomologous end joining	GO:0006303	10	MRE11 MLH1 ATM
12	embryonic organ development	GO:0048568	9.95	TP53 PALB2 CTNNB1
13	signal transduction in response to DNA damage	GO:0006975	9.91	CHEK2 ATM
14	signal transduction in response to DNA damage	GO:0042770	9.91	CHEK2 ATM
15	reciprocal meiotic recombination	GO:0007131	9.89	MRE11 MLH1 ATM
16	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.88	TP53 CHEK2 ATM
17	positive regulation of neuron apoptotic process	GO:0043525	9.87	ATM CTNNB1 MIR200A TP53
18	cellular response to gamma radiation	GO:0071480	9.86	TP53 HRAS CHEK2 ATM
19	replicative senescence	GO:0090399	9.85	TP53 CHEK2 ATM
20	regulation of cell population proliferation	GO:0042127	9.85	TP53 LGR5 HRAS ERBB3 CTNNB1 BRAF
21	neuron apoptotic process	GO:0051402	9.65	ATM ERBB3 HRAS KRAS TP53
22	response to stress	GO:0006950	9.54	MUTYH ATM
23	cellular response to DNA damage stimulus	GO:0006974	9.44	TP53 PALB2 MUTYH MRE11 MLH1 CHEK2